Deflazacort

🧮 Dose calculator

Duchenne muscular dystrophy · Regimen source: FDA Emflaza · 2.2

• • Tablets: round up to the nearest possible dose (any combination of the 4 strengths); suspension: round up to the nearest 0.1 mL. After more than a few days: taper. Moderate/strong CYP3A4 inhibitors: one-third of the dose. Live vaccines 4–6 weeks before starting. FDA Emflaza · 2.2FDA Emflaza · 2.3FDA Emflaza · 2.5FDA Emflaza · 2.1

Enter age and weight.

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Emflaza · 8.1

  “Risk Summary Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Emflaza · 8.2

  “Risk Summary Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects.”

• 👶 ChildrenUse with caution

  The label has conditions, age limits or notes for children; the label sentence is quoted below. FDA Emflaza · 8.4

  “The safety and effectiveness of EMFLAZA for the treatment of DMD have been established in patients 2 years of age and older.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Emflaza · 8.5

  “DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with EMFLAZA.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.